Re: Farmas USA
OCAT
Otra cosa, hoy ha sido el simposio ese de Sevilla.
Y otra publicación de The Company of Biologists en la que sale mencionada:
Retinal degeneration
A major clinical focus of hPSC-derived cell therapy has been the replacement of damaged retinal pigment epithelium (RPE) in the eye. The RPE serves many functions: it absorbs scattered light and supports photoreceptors through phagocytosis of photoreceptor outer segment membranes; it also supplies nutrients and trophic factors, and buffers extracellular ionic changes (Sparrrow et al., 2010). RPE deterioration or malfunction is associated with several retinal dystrophies, including age-related macular degeneration (AMD) and Stargardt’s macular dystrophy (Sunness et al., 1999; Armstrong et al., 1998). In these retinal dystrophies, loss of RPE is associated with loss of photoreceptors as a result of the crucial support provided by the RPE (Sarks et al., 1988; Weng et al., 1999). Based on these findings, there are compelling reasons to think that an hPSC-RPE therapy would have utility for treating these diseases, assuming that sufficient photoreceptors remain at the time of treatment.
Several clinical trials have been advanced to evaluate hPSC- derived RPE in AMD and Stargardt’s disease. The first were initiated in 2011 and sponsored by Advanced Cell Technology/ Ocata Therapeutics. Two open-label Phase 1/2 trials in the United States, one for Stargardt’s disease and one for the more common dry form of AMD, are using a dose-escalation strategy to evaluate safety and efficacy. In parallel, Advanced Cell Technology/Ocata Therapeutics started a Phase 1/2 trial for Stargardt’s disease in the United Kingdom testing the same hPSC-RPE therapeutic.
http://dev.biologists.org/content/142/18/3077.full.pdf
Edito: si no son imbéciles, la semana que viene deberían sacar dos PR: uno de inicio de ensayo en AMD y otro de reclutamiento del primer paciente en SMD
«Después de nada, o después de todo/ supe que todo no era más que nada.»
